Tolnim-D Tablet is a combination of two medicines: Tolperisone and Diclofenac, which relieves pain and relaxes the muscles.
Tolnim-D Tablet is a combination of two medicines: Tolperisone and Diclofenac, which relieves pain and relaxes the muscles. Tolperisone is a muscle relaxant. It works on the centers in the brain and spinal cord to relieve muscle stiffness or spasm and to relieve pain and improve the movement of muscles.
Diclofenac is a non-steroidal anti-inflammatory drug (NSAID) which works by blocking the release of certain chemical messengers that cause pain and inflammation (redness and swelling).
Each Tablet of Tolnim D contains:
- Tolperisone Hydrochloride 150 mg + Diclofenac Sodium 50 mg + Colours: Red Oxide of iron & Titanium Dioxide
Tolnim-D Tablet is unsafe to use during pregnancy as there is definite evidence of risk to the developing baby. However, the doctor may rarely prescribe it in some life-threatening situations if the benefits are more than the potential risks. Please consult your doctor.
Tolnim-D Tablet should be used with caution in patients with kidney disease. Dose adjustment of Tolnim-D Tablet may be needed. Please consult your doctor.
Tolnim-D Tablet should be used with caution in patients with liver disease. Dose adjustment of Tolnim-D Tablet may be needed.
Please consult your doctor.Regular monitoring of liver function tests is recommended in patients with liver disease if this medicine is to be taken for a long time.
The comparative study of clinical efficacy and safety of baclofen vs tolperisone in spasticity caused by spinal cord injury
Recently, tolperisone has been to be an effective and safe muscle relaxant for patients with spasticity. It stabilizes nerve membrane and inhibits pathologic mono- and polysynaptic reflex activity (Dulin et al., 1998; Pratzel et al., 1996). Unlike other muscle relaxants, tolperisone has no substantial affinity to cholinergic, serotonergic, dopaminergic or adrenergic receptors in the central nervous system, thus without sedation or withdrawal phenomenon (Dulin et al., 1998). However, there are very few trials available which ensures the clinical efficacy and safety of tolperisone. In addition, only few studies are available assessing the clinical efficacy and safety of tolperisone in spasticity after stroke and no studies are available for SCI and CP related spasticity (Stamenova et al., 2006; Rahman et al., 2017; Sarfraz et al., 2017). The aim of the present study is to compare and evaluate the clinical efficacy and safety of baclofen vs tolperisone for spasticity of patients with spinal cord injury
Disclaimer: The information produced here is best of our knowledge and experience and we have tried our best to make it as accurate and up-to-date as possible, but we would like to request that it should not be treated as a substitute for professional advice, diagnosis or treatment. For more information we strongly recommend you see a doctor immediately.